Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We analyzed data on the expressions of phosphorylated AKT1 and MYC and the concentrations of 228 metabolites from 60 human prostate tumor samples and 16 normal tissue samples.
|
30340213 |
2018 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
|
29295717 |
2018 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.
|
23704919 |
2013 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Behavioral stress inhibited apoptosis and delayed prostate tumor involution both in phosphatase and tensin homolog-deficient (PTEN-deficient) prostate cancer xenografts treated with PI3K inhibitor and in prostate tumors of mice with prostate-restricted expression of c-MYC (Hi-Myc mice) subjected to androgen ablation therapy with bicalutamide.
|
23348742 |
2013 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
On the basis of our results, we conclude that elevated C-MYC expression in primary prostate tumor is biologically relevant and may be a predictor of future biochemical recurrence.
|
20820186 |
2010 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Analysis of MYC and the mTOR pathway in human prostate tumors and PrEC showed selective increased expression of eukaryotic initiation factor 4E-binding protein 1 (4EBP1) with gain in MYC copy number or forced MYC expression, respectively.
|
19773438 |
2009 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells.
|
18623111 |
2009 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.
|
18567993 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Expression profiling analysis and modeling of transcriptional regulatory networks predicts a functional association between MYC and the prostate tumor suppressor KLF6.
|
18190704 |
2008 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Expression profiling analysis and modeling of transcriptional regulatory networks predicts a functional association between MYC and the prostate tumor suppressor KLF6.
|
18190704 |
2008 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk.
|
18483343 |
2008 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Taken together, these data combining cell culture and animal models and human prostate tumors reveal that ERG overexpression in prostate tumor cells may contribute to the neoplastic process by activating C-MYC and by abrogating prostate epithelial differentiation as indicated by prostate epithelial specific markers.
|
18542058 |
2008 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Does the inhibition of c-myc expression mediate the anti-tumor activity of PPAR's ligands in prostate cancer cell lines?
|
17466258 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Integrative molecular concept modeling of prostate cancer progression.
|
17173048 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
|
15937962 |
2005 |